Natsuda Aumpan

Natsuda Aumpan

Auto-generated profile, based on publicly available information

Natsuda Aumpan

Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Thailand; Department of Medicine, Chulabhorn International College of Medicine (CICM), Thammasat University, Thailand

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2022 in JGH Open
Verified
Journal Article
Open access
NANatsuda Aumpan
Natsuda Aumpan
VMVarocha Mahachai
Varocha Mahachai
RVRatha-korn Vilaichone
Ratha-korn Vilaichone
Helicobacter pylori infection exhibits a wide disease spectrum ranging from asymptomatic gastritis, peptic ulcer disease, to gastric cancer. H. pylori can induce dysbiosis of gastric microbiota in the pathway of carcinogenesis and successful eradication can restore gastric homeostasis. Diagnostic testing and treatment for H. pylori infection is recommended in patients with active or past history of peptic ulcer, chronic dyspepsia, chronic non‐steroidal anti‐inflammatory drugs (NSAID) or aspirin use, precancerous gastric lesions, gastric cancer, mucosa‐associated lymphoid tissue (MALT) lymphoma, family history of gastric cancer, family history of peptic ulcers, household family member having active H. pylori infection, iron deficiency anemia, idiopathic thrombocytopenic purpura, or vitamin B12 deficiency. Recommended first‐line regimens for H. pylori eradication are classified according to clarithromycin resistance. In areas of high clarithromycin resistance (≥15%), we recommend 14‐day concomitant therapy or 14‐day bismuth quadruple therapy (BQT) as first‐line regimen. In areas of low clarithromycin resistance (<15%), we recommend 14‐day triple therapy or 14‐day BQT as first‐line treatment. Second‐line regimens are 14‐day levofloxacin triple therapy or 14‐day BQT if BQT is not previously used. For patients with multiple treatment failure, antimicrobial susceptibility testing (AST) should be performed. If AST is not available, we recommend using antibiotics not previously used or for which resistance is unlikely, such as amoxicillin, tetracycline, bismuth, or furazolidone. High‐dose potent proton pump inhibitor or vonoprazan is recommended to achieve adequate acid suppression. Probiotics can be used as an adjuvant treatment to reduce the side effects of antibiotics and enhance eradication rate.

11 August 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NANatsuda Aumpan
Natsuda Aumpan
RVRatha-korn Vilaichone
Ratha-korn Vilaichone
BPBubpha Pornthisarn
Bubpha Pornthisarn
SCSoonthorn Chonprasertsuk
Soonthorn Chonprasertsuk
SSSith Siramolpiwat
Sith Siramolpiwat
Yoshio YamaokaYoshio Yamaoka
Yoshio Yamaoka
Background: Gastric intestinal metaplasia (IM) can lead to gastric cancer. Until now, there have been limited studies of predictors for regression and progression of IM. This study aimed to determine risk factors associated with regression or progression of IM for guiding proper management and prevention of gastric cancer. Methods: 2,025 patients undergoing gastroscopy in Thammasat University Hospital, Thailand were enrolled during September 2017-August 2019. Patients’ data including baseline characteristics, laboratory results, and histopathology of gastric biopsies from University medical database were extensively reviewed. Results: 2,025 patients had mean age of 61.3 years and 44.2% were males. Overall H. pylori prevalence was 47.5%. There were 1,551(76.6%) patients with chronic gastritis and 361(17.8%) with IM. Of 400 patients with chronic gastritis having follow-up endoscopy and repeated gastric biopsies, 104(26%) had persistent H. pylori infection and 27(26%) developed IM during mean follow-up time of 24 months. Persistent H. pylori infection was significantly associated with development of IM (OR 3.16, 95%CI 1.56–6.39, p = 0.001). Regression, persistence, and progression of IM were demonstrated in 57.3%, 39.2%, and 3.5% of patients, respectively. Age >65 years, persistent H. pylori infection, and diabetes mellitus were significantly associated with persistent IM or progression to dysplasia with OR 2.47(95%CI 1.33–4.61, p = 0.004), OR 2.64(95%CI 1.13–6.18, p = 0.025), and OR 2.54(95%CI 1.16–5.54, p = 0.019), respectively. Patients without H. pylori infection had more IM regression than patients with persistent infection (60.4%vs.39.4%, p = 0.035). Patients with persistent H. pylori infection significantly had higher IM progression to dysplasia (15.2%vs.2.1%; OR 11.15, 95%CI 1.18–105.24, p = 0.035) than noninfected. During 24 months of study, 30 patients (1.5%) were diagnosed with gastric cancer. Conclusion: Regression of IM could be achieved by successful H. pylori eradication. Persistent H. pylori infection was significantly associated with development and progression of IM to dysplasia. Age >65 years and diabetes mellitus were also significant predictors for IM progression.

30 November 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NANatsuda Aumpan
Natsuda Aumpan
NINavapan Issariyakulkarn
Navapan Issariyakulkarn
VMVarocha Mahachai
Varocha Mahachai
DGDavid Graham
David Graham
Yoshio YamaokaYoshio Yamaoka
Yoshio Yamaoka
RVRatha-korn Vilaichone
Ratha-korn Vilaichone
Background: Helicobacter pylori treatment failure remains a challenging problem. This study aimed to identify predictive factors for successful eradication in patients following treatment failures. Methods: This was a retrospective cohort study. This study included 1,050 dyspeptic patients diagnosed with H. pylori infection at tertiary care center in Thailand between March 2014 and October 2021. Patients’ demographic data, endoscopic findings, H. pylori culture, antimicrobial susceptibility testing (AST), treatment regimens and outcomes were analysed. Results: Of 1,050 patients with H. pylori infections, 302 (28.7%) experienced treatment failure (mean age 58.4 years; 44.7% males). AST was performed in 192. Resistance was observed for metronidazole (43.2%), levofloxacin (33.9%), clarithromycin (24%), and amoxicillin (2.1%). There was no tetracycline resistance. Multidrug-resistance (MDR) was significantly more common following treatment failure (45.5% vs. 15.7%, p<0.001). Baseline characteristics were similar between treatment successes and failures. Eradication rates after first-line and second-line regimens were 71.2% and 54.5%, respectively. Medication nonadherence [OR 36.6 (95%CI 8.65–155.03, p<0.001)] and MDR [OR 4.49 (95%CI 2.29–8.81, p<0.001)] were associated with treatment failure. Over time, resistance increased for metronidazole, levofloxacin, and clarithromycin, while eradication rates with triple therapy declined. Tailored antibiotic therapy [OR 4.92 (95%CI 1.61–14.99, p = 0.005)] and a regimen including 4-times-daily dosing of amoxicillin (2 grams/day) [OR 3.05 (95%CI 1.10–8.41, p = 0.032)] were significantly associated with treatment success after first-line failure. Eradication rates when using tailored therapy and 4-times-daily dosing of amoxicillin (2 grams/day) were 91.1% and 89.4%, respectively. Performing AST before first-line therapy resulted in the highest cure rates. AST performed after multiple treatment failures was also associated with higher eradication rates compared with the group without AST (94.4% vs. 50%,p = 0.008). Conclusions: AST either before or after treatment failure correlated with a higher proportion of successful eradication. Nonadherence and the MDR infections predicted treatment failure. Tailored therapy and 4-times-daily dosing of amoxicillin after treatment failure were likely to be successful.

1 August 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
RVRatha-korn Vilaichone
Ratha-korn Vilaichone
NANatsuda Aumpan
Natsuda Aumpan
TRThawee Ratanachu-Ek
Thawee Ratanachu-Ek
TUTomohisa Uchida
Tomohisa Uchida
LTLotay Tshering
Lotay Tshering
Yoshio YamaokaYoshio Yamaoka
Yoshio Yamaoka
Bhutan suffers from a high prevalence of Helicobacter pylori (H. pylori) infection and gastric cancer-related mortality. In preparation for a country-wide H. pylori eradication program the antibiotic resistance patterns of H. pylori infection were surveyed in different geographical regions. Dyspeptic patients in 6 districts including Thimphu, Punakha, Wangdue, Trongsa, Bumthang, and Haa underwent upper gastrointestinal endoscopy during GASTROCAMP and were enrolled between December 2010 and April 2015. Gastric biopsies were obtained for rapid urease test, histopathology, andH. pylori culture. Antimicrobial susceptibility testing was later performed if the culture was positive. A total of 1,178 were surveyed. The overallH. pylori infection in Bhutan was 66.2%. Punakha had the highest prevalence of H. pylori infection (85.6%). Thimphu and Punakha (city areas) had higher prevalence of H. pylori infection than rural districts (73.5% vs 63.3%, OR = 1.61, 95% CI 1.22-2.13, p = 0.0008). There were 357 patients (30.3%) with positive H. pylori culture completed antimicrobial susceptibility testing. The mean age was 40.5 years with female predominance (57.1%). No amoxicillin resistant strains found. Metronidazole resistant was 81% followed by levofloxacin resistance (8.1%). Clarithromycin (2%) and tetracycline (0.6%) resistance was rare except in Thimphu, the capital city (10%) vs 0% in rural areas, p < 0.001. The MNZ-resistant rate remained stable at approximately 80% during the past 5 years of study. LVX-resistant strains gradually rose from 5.3% in 2010 to 9.9% in 2015. Bhutan had a high prevalence of H. pylori infection. Metronidazole resistance was extremely high, whereas clarithromycin resistance was quite low in this specific area. Antibiotic resistance pattern could be good evidence for guiding a proper treatment regimen for H. pylori infection in Bhutan.

12 September 2020 in JGH Open
Verified
Journal Article
Open access
PDF file
NANatsuda Aumpan
Natsuda Aumpan
PNPongjarat Nunanan
Pongjarat Nunanan
RVRatha-korn Vilaichone
Ratha-korn Vilaichone
Background and Aim: Coronavirus disease 19 (COVID‐19) has caused over 200 000 deaths worldwide. Thailand announced the first confirmed case outside mainland China in January 2020. The disease also spread widely across Association of Southeast Asian Nations (ASEAN). Gastrointestinal manifestations could be presenting symptoms of COVID‐19. This study aimed to determine the prevalence of gastrointestinal manifestations of COVID‐19 patients in Thailand and review important aspects of this disease in ASEAN.Methods: Thai patients diagnosed with COVID‐19 at Thammasat University Hospital, Thailand, were evaluated between 1 January 2020 and 30 April 2020. Patients' data, clinical presentation, exposure risk, past medical history, laboratory results, and treatment outcomes were extensively reviewed.Results: A total of 352 COVID‐19 tests were performed, and 40 patients with positive tests were studied. The mean age was 30.5 years, and 55% were female. Most (82.5%) had no underlying diseases. Comorbidities were associated with severe COVID‐19 (odds ratio [OR] 29.93; 95% confidence interval [CI] 2.31–388.40, P = 0.009). Gastrointestinal symptoms were present in 12 patients (30%). The most common presenting symptoms were anorexia (17.5%) and diarrhea (15%). Gastrointestinal symptoms developed before (9.1%), concurrent with (63.6%), and after (27.3%) respiratory symptoms. Diarrhea was significantly associated with severe COVID‐19 (OR 38.52; 95% CI 3.11–476.70, P = 0.004). Twenty‐four patients (60%) received antiviral drugs; 40% had only supportive care. Only one patient required intensive care. No patient died.Conclusions: Gastrointestinal manifestations in COVID‐19 patients are common symptoms and can occur anytime during the disease course. Patients presenting with only gastrointestinal symptoms should raise clinical suspicion for COVID‐19 in areas with high disease incidence. Clinically severe COVID‐19 was associated with comorbidities and diarrhea.